The role of VEGF-A in glomerular development and function

Current Opinion in Nephrology and Hypertension

Volumn 13, Issue 1, 2004, Pages 9-15

  Eremina, Vera ^a   Quaggin, Susan E ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Glomerulus; Nephrogenesis; Podocyte; VEGF A

Indexed keywords

ISOPROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ALLELE; AUTOCRINE EFFECT; CELL PROLIFERATION; ENDOTHELIUM CELL; ENZYME REGULATION; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GLOMERULOPATHY; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; KIDNEY DEVELOPMENT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; NONHUMAN; PODOCYTE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL MEMBRANE PERMEABILITY; ENDOTHELIAL CELLS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY GLOMERULUS; PRE-ECLAMPSIA; PREGNANCY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3242749316     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200401000-00002     Document Type: Review

References (55)

1. Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 1999; 237:41-57.
2. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 2002; 196:1497-1506.
3. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002; 8:841-849.
4. Bates DO, Cui TG, Doughty JM, et al. VEGF 165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002; 62:4123-4131. Describes the identification of novel inhibitory VEGF isoforms that are likely important for regulation of VEGF function in normal development and disease states.
5. Hiratsuka S, Minowa O, Kuno J, et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A 1998; 95:9349-9354.
6. Robert B, Zhao X, Abrahamson DR. Coexpression of neuropilin-1, flk1, and VEGF(164) in developing and mature mouse kidney glomeruli [In Process Citation]. Am J Physiol Renal Physiol 2000; 279:F275-F282.
7. Foster RR, Hole R, Anderson K, et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 2003; 284:F1263-F1273. This paper demonstrates that inhibition of Type III tyrosine kinase receptors in human cultured podocytes leads to inhibition of a VEGF-mediated response. Suggests that an autocrine loop for VEGF signaling may exist within the podocyte.
8. Freeburg PB, Robert B, St John PL, Abrahamson DR. Podocyte expression of hypoxia-inducible factor (HIF)-1 and HIF-2 during glomerular development. J Am Soc Nephrol 2003; 14:927-938.
9. Abrahamson DR. Glomerulogenesis in the developing kidney. Semin Nephrol 1991; 11:375-389.
10. Satchell SC, Mathieson PW. Angiopoietins: microvascular modulators with potential roles in glomerular pathophysiology. J Nephrol 2003; 16:168-178.
11. Partanen TA, Arola J, Saaristo A, et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 2000; 14:2087-2096.
12. Satchell SC, Harper SJ, Tooke JE, et al. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 2002; 13:544-550.
13. Kolatsi-Joannou M, Li XZ, Suda T, et al. Expression and potential role of angiopoietins and Tie-2 in early development of the mouse metanephros. Dev Dyn 2001; 222:120-126.
14. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999; 286:2511-2514.
15. Partanen J, Puri MC, Schwartz L, et al. Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during murine development. Development 1996; 122:3013-3021.
16. Fan L, Wakayama T, Yokoyama S, et al. Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis. Nephron 2002; 90:95-102.
17. Honkanen EO, Teppo AM, Gronhagen-Riska C. Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis. Kidney Int 2000; 57:2343-2349.
18. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model. I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001; 12:1434-1447.
19. de Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12:993-1000.
20. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380:435-439.
21. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439-442.
22. Kitamoto Y, Tokunaga H, Tomita K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J Clin Invest 1997; 99:2351-2357.
23. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development 1999; 126:1149-1159.
24. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Inves 2003; 111:707-716. Using cell-specific gene targeting, the allele dose of VEGF was altered ONLY in the podocyte. Each VEGF genotype was associated with a dramatic and distinct glomerular phenotype demonstrating an exquisite dosage-sensitivity for VEGF within the developing glomerulus. The glomerular phenotypes resembled congenital nephropathy, endotheliosis of preeclampsia and HIV-associated nephropathy.
25. Takahashi T, Takahashi K, Gerety S, et al. Temporally compartmentalized expression of ephrin-B2 during renal glomerular development. J Am Soc Nephrol 2001; 12:2673-2682.
26. McCright B, Gao X, Shen L, et al. Defects in development of the kidney, heart and eye vasculature in mice homozygous for a hypomorphic Notch2 mutation. Development 2001; 128:491-502.
27. Kang DH, Anderson S, Kim YG, et al. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 2001; 37:601-611.
28. Mattot V, Moons L, Lupu F, et al. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol 2002; 13:1548-1560. Mice that express only the 120 isoform of VEGF demonstrate defects in glomerular development.
29. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001; 108:349-355.
30. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 1997; 15:180-189.
31. Rivilis I, Milkiewicz M, Boyd P, et al. Differential involvement of MMP-2 and VEGF during muscle stretch- versus shear stress-induced angiogenesis. Am J Physiol Heart Circ Physiol 2002; 283:H1430-H1438.
32. Lin R, Amizuka N, Sasaki T, et al. 1Alpha,25-dihydroxyvitamin D3 promotes vascularization of the chondro-osseous junction by stimulating expression of vascular endothelial growth factor and matrix metalloproteinase 9. J Bone Min Res 2002; 17:1604-1612.
33. Lelongt B, Bengatta S, Delauche M, et al. Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J Exp Med 2001; 193:793-802.
34. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658. Identified elevated levels of sFlt-1 in patients with preeclampsia and showed that injection of rats with an adenoviral vector encoding sFlt-1 led to endotheliosis, hypertension and proteinuria, the clinical signs of preeclampsia. Together, their results provide a plausible hypothesis for organ dysfunction in preeclampsia that can be tested prospectively in patients.
35. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278:12605-12608. Injection of a chimeric sFlt-1Fc antibody that neutralized circulating VEGF levels led to proteinuria and redistribution of the slit diaphragm protein, nephrin.
36. Kitamoto Y, Takeya M, Tokunaga H, et al. Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. Tohoku J Exp Med. 2001 Sep;195(1):43-54
37. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
38. Drake CJ, Little CD. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Proc Natl Acad Sci USA 1995; 92:7657-7661.
39. Drake CJ, Little CD. VEGF and vascular fusion: implications for normal and pathological vessels. J Histochem Cytochem 1999; 47:1351-1356.
40. Morini M, Benelli R, Giunciuglio D, et al. Kaposi's sarcoma cells of different etiologic origins respond to HIV-Tat through the Flk-1/KDR (VEGFR-2): relevance in AIDS-KS pathology. Biochem Biophys Res Commun 2000; 273:267-271.
41. Ganju RK, Munshi N, Nair BC, et al. Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol 1998; 72:6131-6137.
42. Vene R, Benelli R, Noonan DM, Albini A. HIV-Tat dependent chemotaxis and invasion, key aspects of tat mediated pathogenesis. Clin Exp Metastasis 2000; 18:533-538.
43. Marras D, Bruggeman LA, Gao F, et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 2002; 8:522-526.
44. Yang B, Cross DF, Ollerenshaw M, et al. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications 2003; 17:1-6.
45. Breslin JW, Pappas PJ, Cerveira JJ, et al. VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am J Physiol Heart Circ Physiol 2003; 284:H92-H100.
46. Bates DO, Lodwick D, Williams B. Vascular endothelial growth factor and microvascular permeability. Microcirculation 1999; 6:83-96.
47. Zhao Q, Egashira K, Inoue S, et al. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 2002; 105:1110-1115.
48. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol 2003; 458:283-289.
49. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162:1123-1137.
50. Kobayashi T, Kamata K. Short-term insulin treatment and aortic expressions of IGF-1 receptor and VEGF mRNA in diabetic rats. Am J Physiol Heart Circ Physiol 2002; 283:H1761-H1768.
51. Fornoni A, Li H, Foschi A, et al. Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis. Am J Pathol 2001; 158:275-280.
52. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383:73-75.
53. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417:954-958. Describes a private internal autocrine loop for VEGF signaling in hematopoietic stem cell survival. This has clear implications for autocrine signaling in other tissues such as the glomerulus.
54. Harper SJ, Xing CY, Whittle C, et al. Expression of neuropilin-1 by human glomerular epithelial cells in vitro and in vivo. Clin Sci (Lond) 2001; 101:439-446.
55. Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001; 61:5736-5740.